EVOLVE, a study by United Therapeutics to evaluate real-world use of next generation pumps for Remodulin is now enrolling

The aim of the EVOLVE study is to observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generation infusion pumps to administer Remodulin in patients with pulmonary arterial hypertension.

The study requires eligible participants to remotely complete assessments and questionnaires (i.e., no office visits required) using a mobile app over a period of 8 weeks. Eligible participants may enroll in this study at any time before and up to 10 days after starting subcutaneous Remodulin therapy using the Remunity pump for Remodulin (treprostinil) injection for pulmonary arterial hypertension (PAH). Participants may have other medical data about them recorded, such as medical history.

Read more about the EVOLVE study at this link on the clinicaltrials.gov website

Scroll to Top